Novo Nordisk launches weight-loss drug Wegovy in UK

By Maggie Fick

LONDON (Reuters) – Novo Nordisk (NYSE:) launched its weight-loss injection Wegovy in Britain on Monday, its second debut in Europe in just over a month as the drugmaker seeks to expand in the region even as it struggles to keep up with soaring demand.

The Danish drugmaker said in a statement that Wegovy would be available in the UK “through a controlled and limited launch”.

Surging demand for the drug, and Novo’s highly effective diabetes drug Ozempic, have sent the company’s shares and earnings to record highs. On Friday it unseated LVMH as Europe’s most valuable listed company, ending the French luxury group’s 2-1/2 year-long reign at the top.

Wegovy, shown to help patients reduce body weight by around 15% when used along with exercise and lifestyle changes, is so far available in the United States, Norway, Denmark, and as of late July, Germany.

Novo’s inability to keep up with U.S. demand for Wegovy has effectively delayed the launch in most of Europe.

The company has struggled to keep up with demand even as it has added production capacity, and its CEO told Reuters last month it would “take quite some years” before the company can satisfy the whole market.

“We are closely monitoring Wegovy demand and are working with regulators and providers to ensure people living with obesity can have access to and remain on treatment,” the company said in its statement.

In March, Britain’s drug cost-effectiveness watchdog NICE recommended the use of Wegovy in adults with at least one weight-related condition and a body mass index of 35, but only within the National Health Service’s (NHS) specialist weight management scheme.

Novo’s statement noted that the drug will be available both within the National Health Service’s weight management scheme and “privately through a registered healthcare professional”.

Novo did not say how much supply it would make available in the UK or how much Wegovy would cost in either of the two treatment scenarios it mentioned. In the United States, the drug sells for as much as $1,350 a month.

It was not immediately clear what the implications would be of the drug being available through private healthcare professionals.

“As we expect supply to be constrained for the foreseeable future, a proportion of available supply will be allocated for use only within the NHS to allow healthcare professionals to implement NICE guidance,” the statement said.

In June, the British government said it planned to launch a pilot programme exploring how new weekly weight-loss shots such as Wegovy can be given to obese patients by general practitioners, though at the time Wegovy’s launch date was unknown.

Reuters reported last week that supplies of Wegovy were limited in Germany less than a month after its launch in Europe’s largest drug market, highlighting the challenge for Novo’s ambitions in Europe.